 TEL-AVIV, Israel, April 26, 2021 PRNewswire -- Chemomab Therapeutics, Ltd. Nasdaq: CMMB, a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis NASH. 